Intravenous magnesium for chronic complex regional pain syndrome type 1 (CRPS-1)

Pain Medicine (United States)

Volumn 14, Issue 9, 2013, Pages 1388-1399

  Fischer, Sigrid G L ^a,b,c   Collins, Susan ^a,b,c   Boogaard, Sabine ^a,b,c   Loer, Stephan A ^a   Zuurmond, Wouter W A ^a,c   Perez, Roberto S G M ^a,b,c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c Trauma Related Neuronal Dysfunction (TREND)   (Netherlands)

Author keywords

Central Sensitization; CRPS 1; Magnesium; NMDA Receptor

Indexed keywords

MAGNESIUM SULFATE; PLACEBO;

ADULT; ANALGESIA; ARTICLE; CHRONIC COMPLEX REGIONAL PAIN SYNDROME TYPE 1; CHRONIC PAIN; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SHORT FORM 36; SITTING; TREATMENT RESPONSE; WALKING; WORK CAPACITY;

CENTRAL SENSITIZATION; CRPS-1; MAGNESIUM; NMDA RECEPTOR;

ADULT; ANALGESICS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MAGNESIUM SULFATE; MALE; MIDDLE AGED; PAIN THRESHOLD; QUALITY OF LIFE; RECEPTORS, N-METHYL-D-ASPARTATE; REFLEX SYMPATHETIC DYSTROPHY;

EID: 84883772437     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12211     Document Type: Article

References (49)

1. Harden RN, Bruehl S, Stanton-Hicks M, Wilson PR. Proposed new diagnostic criteria for complex regional pain syndrome. Pain Med 2007;8(4):326-331.
2. Schwartzman RJ, Alexander GM, Grothusen J. Pathophysiology of complex regional pain syndrome. Expert Rev Neurother 2006;6(5):669-681.
3. Woolf CJ. Central sensitization: Implications for the diagnosis and treatment of pain. Pain 2011;152(3 suppl):S2-15.
4. Carlton SM, Coggeshall RE. Inflammation-induced changes in peripheral glutamate receptor populations. Brain Res 1999;820(1-2):63-70.
5. Yang X, Yang HB, Xie QJ, Liu XH, Hu XD. Peripheral inflammation increased the synaptic expression of NMDA receptors in spinal dorsal horn. Pain 2009;144(1-2):162-169.
6. Collins S, Zuurmond WW, de Lange JJ, van Hilten BJ, Perez RS. Intravenous magnesium for complex regional pain syndrome type 1 (CRPS 1) patients: A pilot study. Pain Med 2009;10(5):930-940.
7. Sigtermans MJ, van Hilten JJ, Bauer MC, etal. Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. Pain 2009;145(3):304-311.
8. Collins S, Sigtermans MJ, Dahan A, Zuurmond WW, Perez RS. NMDA receptor antagonists for the treatment of neuropathic pain. Pain Med 2010;11(11):1726-1742.
9. Sigtermans M, Noppers I, Sarton E, etal. An observational study on the effect of S+-ketamine on chronic pain versus experimental acute pain in Complex Regional Pain Syndrome type 1 patients. Eur J Pain 2010;14(3):302-307.
10. Sigtermans M, Dahan A, Mooren R, etal. S(+)-ketamine effect on experimental pain and cardiac output: A population pharmacokinetic-pharmacodynamic modeling study in healthy volunteers. Anesthesiology 2009;111(4):892-903.
11. Herroeder S, Schonherr ME, De Hert SG, Hollmann MW. Magnesium-Essentials for anesthesiologists. Anesthesiology 2011;114(4):971-993.
12. Brill S, Sedgwick PM, Hamann W, Di Vadi PP. Efficacy of intravenous magnesium in neuropathic pain. Br J Anaesth 2002;89(5):711-714.
13. Crosby V, Wilcock A, Corcoran R. The safety and efficacy of a single dose (500mg or 1g) of intravenous magnesium sulfate in neuropathic pain poorly responsive to strong opioid analgesics in patients with cancer. J Pain Symptom Manage 2000;19(1):35-39.
14. Zygmunt M, Heilmann L, Berg C, etal. Local and systemic tolerability of magnesium sulphate for tocolysis. Eur J Obstet Gynecol Reprod Biol 2003;107(2):168-175.
15. Taber EB, Tan L, Chao CR, Beall MH, Ross MG. Pharmacokinetics of ionized versus total magnesium in subjects with preterm labor and preeclampsia. Am J Obstet Gynecol 2002;186(5):1017-1021.
16. Muir KW, Lees KR. Dose optimization of intravenous magnesium sulfate after acute stroke. Stroke 1998;29(5):918-923.
17. Canavero S, Bonicalzi V, Narcisi P. Safety of magnesium-lidocaine combination for severe head injury: The Turin lidomag pilot study. Surg Neurol 2003;60(2):165-169.
18. Levaux C, Bonhomme V, Dewandre PY, Brichant JF, Hans P. Effect of intra-operative magnesium sulphate on pain relief and patient comfort after major lumbar orthopaedic surgery. Anaesthesia 2003;58(2):131-135.
19. Alter HJ, Koepsell TD, Hilty WM. Intravenous magnesium as an adjuvant in acute bronchospasm: A meta-analysis. Ann Emerg Med 2000;36(3):191-197.
20. Miller B, Craddock L, Hoffenberg S, etal. Pilot study of intravenous magnesium sulfate in refractory cardiac arrest: Safety data and recommendations for future studies. Resuscitation 1995;30(1):3-14.
21. Chiladakis JA, Stathopoulos C, Davlouros P, Manolis AS. Intravenous magnesium sulfate versus diltiazem in paroxysmal atrial fibrillation. Int J Cardiol 2001;79(2-3):287-291.
22. Perez RS, Zollinger PE, Dijkstra PU, etal. [Clinical practice guideline "Complex regional pain syndrome type I"]. Ned Tijdschr Geneeskd 2007;151(30):1674-1679.
23. Oerlemans HM, Oostendorp RA, de Boo T, etal. Adjuvant physical therapy versus occupational therapy in patients with reflex sympathetic dystrophy/complex regional pain syndrome type I. Arch Phys Med Rehabil 2000;81(1):49-56.
24. WHO. International Classification of Impairments, Disabilities and Handicaps. Geneva; 2012.
25. Dworkin RH, Turk DC, Farrar JT, etal. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113(1-2):9-19.
26. Peters ML, Patijn J, Lame I. Pain assessment in younger and older pain patients: Psychometric properties and patient preference of five commonly used measures of pain intensity. Pain Med 2007;8(7):601-610.
27. van der Kloot WA, Oostendorp RA, van der Meij J, van den Heuvel J. [The Dutch version of the McGill pain questionnaire: A reliable pain questionnaire]. Ned Tijdschr Geneeskd 1995;139(13):669-673.
28. Melzack R. The McGill Pain Questionnaire: Major properties and scoring methods. Pain 1975;1(3):277-299.
29. Bell-Krotoski J, Weinstein S, Weinstein C. Testing sensibility, including touch-pressure, two-point discrimination, point localization, and vibration. J Hand Ther 1993;6(2):114-123.
30. Bell-Krotoski JA, Fess EE, Figarola JH, Hiltz D. Threshold detection and Semmes-Weinstein monofilaments. J Hand Ther 1995;8(2):155-162.
31. Collins S, Visscher P, de Vet HC, Zuurmond WW, Perez RS. Reliability of the Semmes Weinstein Monofilaments to measure coetaneous sensibility in the feet of healthy subjects. Disabil Rehabil 2010;32(24):2019-2027.
32. Oerlemans HM, Goris RJ, Oostendorp RA. Impairment level sumscore in reflex sympathetic dystrophy of one upper extremity. Arch Phys Med Rehabil 1998;79(8):979-990.
33. Perez RS, Oerlemans HM, Zuurmond WW, de Lange JJ. Impairment level SumScore for lower extremity Complex Regional Pain Syndrome type I. Disabil Rehabil 2003;25(17):984-991.
34. Oerlemans HM, Cup EH, DeBoo T, Goris RJ, Oostendorp RA. The Radboud skills questionnaire: Construction and reliability in patients with reflex sympathetic dystrophy of one upper extremity. Disabil Rehabil 2000;22(5):233-245.
35. Roorda LD, Molenaar IW, Lankhorst GJ, Bouter LM. Improvement of a questionnaire measuring activity limitations in rising and sitting down in patients with lower-extremity disorders living at home. Arch Phys Med Rehabil 2005;86(11):2204-2210.
36. Noonan VK, Miller WC, Noreau L. A review of instruments assessing participation in persons with spinal cord injury. Spinal Cord 2009;47(6):435-446.
37. Brazier J, Jones N, Kind P. Testing the validity of the EuroQol and comparing it with the SF-36 health survey questionnaire. Qual Life Res 1993;2(3):169-180.
38. Konig HH, Ulshofer A, Gregor M, etal. Validation of the EuroQol questionnaire in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002;14(11):1205-1215.
39. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67(6):361-370.
40. Vlaeyen JW, Linton SJ. Fear-avoidance and its consequences in chronic musculoskeletal pain: A state of the art. Pain 2000;85(3):317-332.
41. Kraaimaat FW, Evers AW. Pain-coping strategies in chronic pain patients: Psychometric characteristics of the pain-coping inventory (PCI). Int J Behav Med 2003;10(4):343-363.
42. Perez RS, Zuurmond WW, Bezemer PD, etal. The treatment of complex regional pain syndrome type I with free radical scavengers: A randomized controlled study. Pain 2003;102(3):297-307.
43. Latremoliere A, Woolf CJ. Central sensitization: A generator of pain hypersensitivity by central neural plasticity. J Pain 2009;10(9):895-926.
44. McCabe CS, Haigh RC, Blake DR. Mirror visual feedback for the treatment of complex regional pain syndrome (type 1). Curr Pain Headache Rep 2008;12(2):103-107.
45. Almoznino G, Ben-Chetrit E. Infliximab for the treatment of resistant oral ulcers in Behcet's disease: A case report and review of the literature. Clin Exp Rheumatol 2007;25(4 suppl 45):S99-102.
46. Lin CY, Tsai PS, Hung YC, Huang CJ. L-type calcium channels are involved in mediating the anti-inflammatory effects of magnesium sulphate. Br J Anaesth 2010;104(1):44-51.
47. Hettne KM, de Mos M, De Bruijn AG, etal. Applied information retrieval and multidisciplinary research: New mechanistic hypotheses in complex regional pain syndrome. J Biomed Discov Collab 2007;2:2.
48. de Mos M, Laferriere A, Millecamps M, etal. Role of NFkappaB in an animal model of complex regional pain syndrome-type I (CRPS-I). J Pain 2009;10(11):1161-1169.
49. Hirota K, Lambert DG. Ketamine: Its mechanism(s) of action and unusual clinical uses. Br J Anaesth 1996;77(4):441-444.